Levofolic (Levoleucovorin Disodium)

Levoleucovorin disodium is a reduced folate that bypasses the enzyme dihydrofolate reductase, directly entering the folate cycle as 5‑methyltetrahydrofolate. This replenishes intracellular reduced folates, supporting DNA synthesis and methylation, thereby counteracting the inhibition caused by antifolate drugs.

The dosage of Levofolic is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and the chemotherapy regimen involved. Only a qualified healthcare professional should set the appropriate dose.

Levofolic should be used during pregnancy or lactation only if clearly needed and after a risk‑benefit assessment by the prescriber. Limited data are available, so the decision must be individualized and discussed with a healthcare provider.

To order Levofolic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Levofolic (levoleucovorin disodium) is a reduced folate similar to folinic acid but supplied as a sodium salt for intravenous use. Compared with oral folic acid, it provides more rapid and reliable restoration of intracellular folate pools, making it preferred for acute rescue after high‑dose antifolate chemotherapy.

Levofolic must be stored at 2‑8 °C (refrigerated), protected from light, and should never be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Levofolic is administered by intravenous infusion, typically diluted in an appropriate compatible solution and infused over a period defined by the treating physician, often following or preceding chemotherapy according to the clinical protocol.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal dysfunction, significant electrolyte disturbances, and rare thromboembolic events. Prompt recognition and medical intervention are essential if any of these occur.

Levofolic should be avoided in patients with known hypersensitivity to levoleucovorin or any component of the formulation, and caution is advised in individuals with severe renal impairment or uncontrolled electrolyte abnormalities until evaluated by a healthcare professional.